IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v24y2023i2d10.1007_s10198-022-01470-w.html
   My bibliography  Save this article

Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China

Author

Listed:
  • Phil McEwan

    (Health Economics and Outcomes Research Ltd)

  • James Baker-Knight

    (Novo Nordisk A/S)

  • Björg Ásbjörnsdóttir

    (Novo Nordisk A/S)

  • Yunni Yi

    (Adelphi Values PROVE)

  • Aimee Fox

    (Adelphi Values PROVE)

  • Robin Wyn

    (Adelphi Values PROVE)

Abstract

Introduction Once-daily and once-weekly injectable glucagon-like peptide-1 receptor agonist therapies (GLP-1 RAs) are established in obesity and type 2 diabetes mellitus (T2DM). In T2DM, both once-daily and once-weekly insulin are expected to be available. This study elicited utilities associated with these treatment regimens from members of the general public in the UK, Canada, and China, to quantify administration-related disutility of more-frequent injectable treatment, and allow economic modelling. Methods Two anchor states (no pharmacological treatment), and seven treatment states (daily oral tablet and generic injectable regimens of variable frequency), with identical outcomes were tested A broadly representative sample of the general public in each country participated (excluding individuals with diabetes or pharmacologically treated obesity). An adapted Measurement and Valuation of Health protocol was administered 1:1 in web-enabled interviews by trained moderators: visual analogue scale (VAS) as a “warm-up”, and time trade-off (TTO) using a 20-year time horizon for utility elicitation. Results A total of 310 individuals participated. The average disutility of once-daily versus once-weekly GLP-1 RA was − 0.048 in obesity and − 0.033 in T2DM; the corresponding average disutility for insulin was − 0.064. Disutilities were substantially greater in China, relative to UK and Canada. Discussion Within obesity and T2DM, more-frequent treatment health states had lower utility. Scores by VAS also followed a logical order. The generated utility values are suitable for use in modelling injectable therapy regimens in obesity and T2DM, due to the use of generic descriptions and assumption of equal efficacy. Future research could examine the reasons for greater administration-related disutility in China.

Suggested Citation

  • Phil McEwan & James Baker-Knight & Björg Ásbjörnsdóttir & Yunni Yi & Aimee Fox & Robin Wyn, 2023. "Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(2), pages 187-196, March.
    • Handle: RePEc:spr:eujhec:v:24:y:2023:i:2:d:10.1007_s10198-022-01470-w
    DOI: 10.1007/s10198-022-01470-w
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-022-01470-w
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s10198-022-01470-w?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Mark Oppe & Kim Rand-Hendriksen & Koonal Shah & Juan M. Ramos‐Goñi & Nan Luo, 2016. "EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes," PharmacoEconomics, Springer, vol. 34(10), pages 993-1004, October.
    2. Kristina Boye & Louis Matza & Kimberly Walter & Kate Brunt & Andrew Palsgrove & Aodan Tynan, 2011. "Utilities and disutilities for attributes of injectable treatments for type 2 diabetes," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(3), pages 219-230, June.
    3. Hsiang-Wen Lin & Chia-Ing Li & Fang- Ju Lin & Jen-Yu Chang & Churn-Shiouh Gau & Nan Luo & A Simon Pickard & Juan M Ramos Goñi & Chao-Hsiun Tang & Chien-Ning Hsu, 2018. "Valuation of the EQ-5D-5L in Taiwan," PLOS ONE, Public Library of Science, vol. 13(12), pages 1-16, December.
    4. P. Wang & M. Li & G. Liu & J. Thumboo & N. Luo, 2015. "Do Chinese have similar health-state preferences? A comparison of mainland Chinese and Singaporean Chinese," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(8), pages 857-863, November.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jen-Yu Amy Chang & Chien-Ning Hsu & Juan Manuel Ramos-Goñi & Nan Luo & Hsiang-Wen Lin & Fang-Ju Lin, 2024. "Beyond 10-year lead-times in EQ-5D-5L: leveraging alternative lead-times in willingness-to-accept questions to capture preferences for worse-than-dead states and their implication," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(6), pages 1041-1055, August.
    2. Hobbins, Anna P. & Barry, Luke & Kelleher, Dan & Shah, Koonal & Devlin, Nancy & Ramos Goni, Juan Manuel & O’Neill, Ciaran, 2020. "Do people with private health insurance attach a higher value to health than those without insurance? Results from an EQ-5D-5 L valuation study in Ireland," Health Policy, Elsevier, vol. 124(6), pages 639-646.
    3. Stefan A. Lipman & Liying Zhang & Koonal K. Shah & Arthur E. Attema, 2023. "Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(2), pages 293-305, March.
    4. Anne‐Laure Samson & Erik Schokkaert & Clémence Thébaut & Brigitte Dormont & Marc Fleurbaey & Stéphane Luchini & Carine Van de Voorde, 2018. "Fairness in cost‐benefit analysis: A methodology for health technology assessment," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 102-114, January.
    5. Mihir Gandhi & Marcus Ang & Kelvin Teo & Chee Wai Wong & Yvonne Chung-Hsi Wei & Rachel Lee-Yin Tan & Mathieu F. Janssen & Nan Luo, 2020. "A vision ‘bolt-on’ increases the responsiveness of EQ-5D: preliminary evidence from a study of cataract surgery," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(4), pages 501-511, June.
    6. Kristina Ludwig & J.-Matthias Graf von der Schulenburg & Wolfgang Greiner, 2018. "German Value Set for the EQ-5D-5L," PharmacoEconomics, Springer, vol. 36(6), pages 663-674, June.
    7. Johanna Vásquez & Sergio Botero, 2020. "Hybrid Methodology to Improve Health Status Utility Values Derivation Using EQ-5D-5L and Advanced Multi-Criteria Techniques," IJERPH, MDPI, vol. 17(4), pages 1-18, February.
    8. Fredrick Dermawan Purba & Joke A. M. Hunfeld & Aulia Iskandarsyah & Titi Sahidah Fitriana & Sawitri Supardi Sadarjoen & Juan Manuel Ramos-Goñi & Jan Passchier & Jan J. V. Busschbach, 2017. "The Indonesian EQ-5D-5L Value Set," PharmacoEconomics, Springer, vol. 35(11), pages 1153-1165, November.
    9. Peasgood, Tessa & Bourke, Mackenzie & Devlin, Nancy & Rowen, Donna & Yang, Yaling & Dalziel, Kim, 2023. "Randomised comparison of online interviews versus face-to-face interviews to value health states," Social Science & Medicine, Elsevier, vol. 323(C).
    10. Louis Matza & Sandhya Sapra & John Dillon & Anupama Kalsekar & Evan Davies & Mary Devine & Jessica Jordan & Amanda Landrian & David Feeny, 2015. "Health state utilities associated with attributes of treatments for hepatitis C," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 1005-1018, December.
    11. Koonal K. Shah & Juan Manuel Ramos-Goñi & Simone Kreimeier & Nancy J. Devlin, 2020. "An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(7), pages 1091-1103, September.
    12. Andrew Lloyd & Kim Rand & Cleo Pike & Crispin Ellis, 2024. "Preference-based utility weights for the Individualized Neuromuscular Quality of Life Questionnaire (INQoL), with a focus on non-dystrophic myotonia (NDM)," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(8), pages 1461-1469, November.
    13. Antony P. Martin & Enrico Ferri Grazzi & Claudia Mighiu & Manoj Chevli & Farrukh Shah & Louise Maher & Anum Shaikh & Aliah Sagar & Hayley Hubberstey & Bethany Franks & Juan M. Ramos-Goñi & Mark Oppe &, 2023. "Health state utilities for beta-thalassemia: a time trade-off study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(1), pages 27-38, February.
    14. Zhihao Yang & Kim Rand & Elly Stolk & Jan Busschbach & Nan Luo, 2024. "Exploring non-iterative time trade-off methods for valuation of EQ-5D-5L health states," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(7), pages 1087-1094, September.
    15. Sullivan, Trudy & Hansen, Paul & Ombler, Franz & Derrett, Sarah & Devlin, Nancy, 2020. "A new tool for creating personal and social EQ-5D-5L value sets, including valuing ‘dead’," Social Science & Medicine, Elsevier, vol. 246(C).
    16. Ruixuan Jiang & Thomas Kohlmann & Todd A. Lee & Axel Mühlbacher & James Shaw & Surrey Walton & A. Simon Pickard, 2021. "Increasing respondent engagement in composite time trade-off tasks by imposing three minimum trade-offs to improve data quality," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(1), pages 17-33, February.
    17. Brendan Mulhern & Yan Feng & Koonal Shah & Mathieu F. Janssen & Michael Herdman & Ben Hout & Nancy Devlin, 2018. "Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets," PharmacoEconomics, Springer, vol. 36(6), pages 699-713, June.
    18. Amanda Cole & Koonal Shah & Brendan Mulhern & Yan Feng & Nancy Devlin, 2018. "Valuing EQ-5D-5L health states ‘in context’ using a discrete choice experiment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 595-605, May.
    19. Edward J. D. Webb & Paul Kind & David Meads & Adam Martin, 2024. "COVID-19 and EQ-5D-5L health state valuation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(1), pages 117-145, February.
    20. Christian R. C. Kouakou & Jie He & Thomas G. Poder, 2024. "Estimating the monetary value of a Quality-Adjusted Life-Year in Quebec," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(5), pages 787-811, July.

    More about this item

    Keywords

    Time trade-off (TTO); Type 2 diabetes mellitus (T2DM); Obesity; Insulin; GLP-1 receptor agonist (GLP-1 RA);
    All these keywords.

    JEL classification:

    • I10 - Health, Education, and Welfare - - Health - - - General

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:24:y:2023:i:2:d:10.1007_s10198-022-01470-w. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.